Healome Therapeutics
Birmingham, United Kingdom
◆ Total Raised
$2.7M
◆ Stage
seed
◆ Location
Birmingham, United Kingdom
◆ Founded
2021
◆ Team size
1-10
◆ Links
◆ About Healome Therapeutics
University of Birmingham spinout developing a proprietary eye-drop matrix platform for ocular surface diseases.
◆ What sets it apart
Its eye-drop matrix technology uniquely behaves as a liquid upon application but self-structures into a customizable, clear, protective gel that enhances drug retention and promotes healing for 2–8 hours.
◆ Sectors
◆ Business
Modeltransactional
CustomerPharmaceutical companies developing ocular therapeutics and healthcare providers treating ocular surface diseases
◆ Notable
- Closed an oversubscribed £2 million seed round led by Empirical Ventures in July 2026
- Winner of PITCH @ Med-Tech Expo 2025
- Targeting first-in-human phase 1 trials in 2027
- Raised over £3.2 million in prior grant and funding from Innovate UK, Medical Research Council, and SFC Capital
◆ Backing funds on Raise
- SFC Capitalseed
- Empirical Venturesseed
◆ Funding rounds
8 May 2025
Led by Empirical Ventures
With DEBRA Research, Cure EB, Oshen Bio, SFC Capital
◆ Explore the market
◆ FAQ
What does Healome Therapeutics do?
University of Birmingham spinout developing a proprietary eye-drop matrix platform for ocular surface diseases.
Where is Healome Therapeutics based?
Healome Therapeutics is based in Birmingham, United Kingdom, founded in 2021.
How much has Healome Therapeutics raised?
Healome Therapeutics has raised $2.7M in tracked funding and is currently at the seed stage.
Who has invested in Healome Therapeutics?
Investors in Healome Therapeutics include Empirical Ventures, SFC Capital, DEBRA Research, Cure EB, Oshen Bio, Innovate UK, Medical Research Council and University of Birmingham.